Non-Hodgkin Lymphoma Clinical Trials (April 2026): 1,036 Recruiting Interventional Studies
Last updated: April 21, 2026
Current Clinical Trial Landscape
Active research areas in 2026:
- CD20×CD3 bispecific antibodies moving to first-line: epcoritamab, glofitamab, mosunetuzumab, odronextamab
- CAR-T cell therapy: axi-cel, liso-cel, tisa-cel — now testing earlier lines and combinations
- ADCs: zilovertamab vedotin (ROR1), polatuzumab vedotin combinations
- Next-gen BTK inhibitors and degraders: pirtobrutinib, NX-5948
- Bispecific + lenalidomide combinations for indolent NHL
Standard of care: DLBCL: R-CHOP (first-line), CAR-T or bispecific (relapsed). Follicular: rituximab-based combos, then bispecifics or lenalidomide+rituximab. Mantle cell: BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib). T-cell NHL: CHOP-based, then options limited.
Recruiting Trials by NHL Subtype
Diffuse Large B-Cell Lymphoma (DLBCL)
The most common aggressive NHL — bispecifics and CAR-T are transforming relapsed disease:
- First-line:
- NCT07511114 - Pola-R-CHP+X vs CR-CHOP in previously untreated DLBCL (Phase 3)
- Relapsed/refractory — bispecifics:
- NCT06230224 - Odronextamab vs standard of care in R/R DLBCL (Phase 3)
- NCT06084936 - Glofitamab monotherapy vs investigator's choice in R/R DLBCL (Phase 3)
- ADCs:
- NCT05139017 - Zilovertamab vedotin (ROR1 ADC) + R-CHP in untreated DLBCL (Phase 3)
- NCT06717347 - Zilovertamab vedotin + R-CHP in DLBCL (Phase 3)
- CAR-T:
- NCT07502118 - NexCAR19 (talikabtagene autoleucel) in R/R B-cell malignancies (Phase 3)
Follicular Lymphoma
Indolent but incurable — bispecifics offer new options:
-
- NCT06336318 - Mosunetuzumab vs rituximab in low tumor burden FL (Phase 3)
- NCT06549595 - Surovatamig + rituximab in previously untreated FL (Phase 3)
- NCT06191744 - Subcutaneous epcoritamab + rituximab + lenalidomide in FL (Phase 3)
- NCT06149286 - Odronextamab + lenalidomide in R/R FL (Phase 3)
Mantle Cell Lymphoma
BTK inhibitor resistance is the key challenge — next-gen agents and bispecifics:
-
- NCT05976763 - Continuous vs intermittent zanubrutinib for MCL (Phase 3)
- NCT07409428 - HMPL-760 + R-GemOx vs placebo + R-GemOx in R/R MCL (Phase 3)
Peripheral T-Cell Lymphoma (PTCL)
Rare and aggressive — few approved options beyond CHOP:
-
- NCT06561048 - Soquelitinib vs standard in R/R peripheral T-cell lymphoma (Phase 3)
- NCT06522737 - Duvelisib vs gemcitabine or bendamustine in R/R PTCL (Phase 3)
- NCT07300514 - Golidocitinib maintenance for PTCL (Phase 3)
Cutaneous T-Cell Lymphoma (CTCL)
-
- NCT06470451 - Topical HyBryte vs placebo for CTCL (Phase 3)
Cross-Subtype (BTK Inhibitors)
-
- NCT07516093 - NX-5948 (BTK degrader) vs pirtobrutinib in R/R CLL/SLL (Phase 3)
- NCT05254743 - Pirtobrutinib vs ibrutinib in CLL (Phase 3)
Showing selected notable trials. View all 1,036 recruiting interventional trials on ClinicalTrials.gov.
Frequently Asked Questions
How do I find non-Hodgkin lymphoma clinical trials I'm eligible for?
Enter your NHL details into ClinTrialFinder — including subtype (DLBCL, follicular, mantle cell, marginal zone, T-cell), number of prior therapies, and prior CAR-T or bispecific exposure. The AI matches you with trials in minutes.
What non-Hodgkin lymphoma trials are currently recruiting?
There are 1,036 recruiting interventional trials for NHL including CD20×CD3 bispecific antibodies (epcoritamab, glofitamab, odronextamab), CAR-T cell therapy, BTK inhibitors, ADCs, and novel combinations across all subtypes.
Find NHL Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.
Find Matching Trials
